Study guide

33.3 Genitourinary Pharmacology I: Antimicrobial Classes and Toxicities, and Drug Treatment of UTI, Pyelonephritis, Gonorrhea, Chlamydia, Syphilis, Genital Herpes, Genital Warts, PID, Vaginitis, Prostatitis and Orchitis

Philippine Physician Licensure Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: PLE Structure, Eligibility & Study Strategy

1.1 PLE Format, 2026 Schedule & the Statutory Passing Rule 1.2 Eligibility, Internship, PRC Filing & Test-Day Rules 1.3 Reading the 2025 Tables of Specifications & Building a Study Plan

2 Chapter 2: Physiology I: Cells, Blood, Nerve & Muscle

2.1 Homeostasis, Cell Function, Membrane Transport & Resting Potential 2.2 Blood Cells, Immunity, Hemostasis, Fibrinolysis & Blood Distribution 2.3 Action Potentials, Conduction, the Neuromuscular Junction & Muscle Contraction

3 Chapter 3: Physiology II: Cardiovascular & Respiratory Systems

3.1 Cardiac Electrophysiology, the Cardiac Cycle & the Heart as a Pump 3.2 Circulation: Resistance, Venous Return, Coronary Flow, Microcirculation & Fetal Circulation 3.3 Respiratory Mechanics, Gas Exchange, Gas Transport, Control of Breathing & Extreme Environments

4 Chapter 4: Physiology III: Gastrointestinal, Endocrine, Renal & Reproductive Systems

4.1 Gastrointestinal Physiology: Secretion, Motility, Digestion & Absorption 4.2 Endocrine Physiology: Hormone Chemistry, Axes, Calcium & Fuel Regulation 4.3 Renal Physiology, Body Fluid Balance & Acid-Base Regulation 4.4 Reproductive Physiology: Sexual Differentiation, Spermatogenesis, the Menstrual Cycle, Parturition & Lactation

5 Chapter 5: Physiology IV: Neurophysiology & Special Senses

5.1 Sensory Receptors, Somatic Sensation, Spinal Reflexes & Motor Control 5.2 Higher Brain Functions, Sleep, the Autonomic Nervous System, Cerebral Blood Flow & the Special Senses

6 Chapter 6: Legal Medicine I: Medicolegal Examination, Identification & Death

6.1 The Medicolegal Examination, Physical Evidence & the Crime Scene 6.2 Identification of the Living, the Dead & Skeletal Remains 6.3 Thanatology: Death, Brain Death, Postmortem Changes & Time of Death

7 Chapter 7: Legal Medicine II: Injuries, Sexual Crimes, Reproduction, Mental State & Poisoning

7.1 Physical Injuries: Revised Penal Code Classes, Wounds, Gunshot Injuries, Asphyxia & Burns 7.2 Sexual Crimes, Violence Against Women & Child Abuse 7.3 Medicolegal Aspects of Pregnancy, Delivery, Abortion, Infanticide, Paternity & Marriage 7.4 Disturbance of Mentality: Insanity, Intoxication, Capacity & the Mental Health Act 7.5 Forensic Toxicology & Poisoning: Diagnosis, Evidence, Antidotes & Philippine Laws

8 Chapter 8: Legal Medicine III: Reports, Regulation, Liability & Ethics

8.1 The Medicolegal Report, the Death Certificate, Autopsy Rules & Communicating with Relatives 8.2 Licensure & Regulation of Medical Practice: RA 2382, the Board of Medicine, PRC & Prescribing Laws 8.3 Medical Malpractice: Civil, Criminal & Administrative Liability and Key Philippine Doctrines 8.4 Physician Relationships Under the PMA Code of Ethics: Patients, Colleagues, Allied Health, Students, Industry, HMOs, Hospitals & PhilHealth 8.5 Bioethical Principles, Informed Consent, Confidentiality, End-of-Life & Research Ethics

9 Chapter 9: Pathology I: Cell Injury, Inflammation & Hemodynamics

9.1 Cell Injury, Adaptation, Necrosis, Apoptosis, Accumulations & Calcification 9.2 Acute & Chronic Inflammation, Granulomas, Systemic Effects & Tissue Repair 9.3 Hemodynamic Disorders: Edema, Hemorrhage, Thrombosis, Embolism, Infarction, DIC & Shock

10 Chapter 10: Pathology II: Genetics, Neoplasia, Immunity, Environment & Infection

10.1 Genetic Disorders & Neoplasia: Mendelian, Chromosomal, Non-Classic Inheritance, Tumor Biology & Markers 10.2 Immunopathology: Hypersensitivity, Autoimmunity, Immunodeficiency & Transplant Rejection 10.3 Environmental & Nutritional Pathology: Air Pollution, Tobacco, Metals, Occupational Lung Disease & Deficiency States 10.4 Pathology of Infectious Diseases: Transmission, Tissue Reaction Patterns & Diagnostic Morphology

11 Chapter 11: Pathology III: Gastrointestinal, Cardiovascular & Respiratory Pathology

11.1 Gastrointestinal, Hepatic, Biliary & Pancreatic Pathology 11.2 Cardiovascular & Collagen Pathology: Heart Failure, Congenital, Ischemic, Hypertensive, Valvular, Pericardial & Myocardial Disease 11.3 Respiratory Pathology: Atelectasis, Edema, ARDS, Obstructive & Restrictive Disease, Vascular Disease, Infections, Tumors & Pleura

12 Chapter 12: Pathology IV: Hematopoietic, Genitourinary, Endocrine & Nervous System Pathology

12.1 Hematopoietic Pathology: Anemias, Polycythemia, Bleeding Disorders, DIC & Lymphoid and Myeloid Neoplasms 12.2 Genitourinary Pathology: Glomerular, Tubulointerstitial, Vascular & Cystic Kidney Disease, Renal Tumors, Obstruction & Genital Disorders 12.3 Endocrine Pathology: Pancreas, Adrenal, Parathyroid, Thyroid & Pituitary Disorders 12.4 Nervous System Pathology: Cerebrovascular Disease, Edema & Herniation, Infections, Degenerative & Demyelinating Disease, Tumors

13 Chapter 13: Biochemistry I: Carbohydrate, Protein, Genetic & Energy Biochemistry

13.1 Carbohydrate Chemistry, Digestion, Glycolysis, Pyruvate Dehydrogenase & the Pentose Phosphate Pathway 13.2 Gluconeogenesis, Glycogen, Lipogenesis, Ketogenesis & Hormonal Control of Fuel Metabolism 13.3 Protein Digestion, Amino Acid Catabolism, the Urea Cycle, Heme Synthesis, Porphyrias & Bilirubin Metabolism 13.4 Amino Acids & Proteins: Structure, Properties, Separation, Specialized Products, Collagen & Protein Misfolding in Alzheimer Disease 13.5 Molecular Genetics & Enzymes: Replication, Repair, Gene Expression, Molecular Techniques, Lysosomal Storage Diseases & Enzyme Kinetics 13.6 Bioenergetics, the Citric Acid Cycle, Oxidative Phosphorylation, Muscle Energetics & Nucleotide Metabolism

14 Chapter 14: Biochemistry II: Respiratory, Nutritional, Immunologic & Cardiovascular Biochemistry

14.1 Respiratory Biochemistry: Hemoglobin, Oxygen Binding, Hemoglobinopathies, Thalassemias, Methemoglobin, Buffers & Acid-Base Balance 14.2 Nutrition Biochemistry: Dietary Standards (RENI to PDRI 2015), Food Guides, Protein Quality, Energy Expenditure, Breast Milk, Vitamins, Minerals & Blood Components 14.3 Immunology: Innate & Adaptive Immunity, the Immune Response, Antibodies, Complement, Cytokines & MHC 14.4 Cardiovascular Biochemistry: Cholesterol, Lipoproteins, Dyslipidemias, Atherogenesis, Myocardial Energetics, Biomarkers & Heart Failure

15 Chapter 15: Anatomy I: Thorax, Abdomen, Pelvis & Back

15.1 Thorax: Thoracic Wall, Breast, Pleura & Lungs, Mediastinum, Heart & Great Vessels 15.2 Abdomen: Abdominal Wall & Inguinal Region, Peritoneum, Viscera, Diaphragm & Posterior Abdominal Wall 15.3 Pelvis & Perineum: Bony Pelvis, Pelvic Floor, Pelvic Viscera, Vessels & Nerves, Perineal Pouches & the Anal Canal 15.4 Back & Spinal Column: Vertebrae, Curvatures, Joints, Back Muscles, Spinal Cord, Meninges & Cord Syndromes

16 Chapter 16: Anatomy II: Upper Limb, Lower Limb & Skin

16.1 Upper Limb: Bones, Superficial Veins, Shoulder Muscles, Axilla & Brachial Plexus, Arm, Cubital Fossa, Forearm, Hand & Joints 16.2 Lower Limb: Bones, Venous & Lymphatic Drainage, Thigh, Gluteal Region, Popliteal Fossa, Leg Compartments, Foot, Joints & Gait 16.3 Skin & Appendages: Epidermis, Junctions, Dermis, Subcutaneous Tissue, Fascia, Nerves, Vessels, Lymphatics, Hair, Nails & Glands

17 Chapter 17: Anatomy III: Head, Neck & Histology

17.1 Head I: Skull & Cranial Foramina, Scalp, Face & Parotid, Orbit, Temporal & Infratemporal Fossae, TMJ, Oral Region, Nose & Ear 17.2 Head II: Meninges & Dural Venous Sinuses, Brain Regions & Ventricles, Blood Supply, Cranial Nerves, Pituitary & Pineal, Brainstem Syndromes 17.3 Neck: Cervical Vertebrae & Hyoid, Fascial Layers, Superficial Muscles, Triangles, Root of the Neck, Visceral Layers & Lymphatics 17.4 Histology: Cells, Epithelium & Glands, Connective Tissue & Fat, Cartilage & Bone, Blood & Hematopoiesis, Muscle, Nerve, Vessels, Lymphoid Organs & Organ Histology

18 Chapter 18: Microbiology I: Foundations, Respiratory & Cardiovascular Infections

18.1 Microbiology Foundations: The Organ-System TOS, Specimens & Stains, Gram-Positive and Gram-Negative Bacteria 18.2 Respiratory Infections: Tonsillitis, Sinusitis & Mastoiditis, Bronchitis, Community-Acquired & Severe Pneumonia, Bronchiectasis and Paragonimiasis 18.3 Tuberculosis, Leprosy & Nontuberculous Mycobacteria: Pathogenesis, Diagnosis, NTP Regimens & Prevention 18.4 Cardiovascular Infections: Infective Endocarditis, Rheumatic Fever & Rheumatic Heart Disease, Myocarditis, Pericarditis and Septic Thrombophlebitis

19 Chapter 19: Microbiology II: Gastrointestinal & Nervous System Infections

19.1 Gastrointestinal Infections I: Gastroenteritis & Enterocolitis, Cholera, Typhoid & Salmonellosis, Shigellosis, Food Poisoning and Viral Hepatitis 19.2 Gastrointestinal Infections II: Amebiasis, Giardiasis & Cryptosporidiosis, Soil-Transmitted Helminths, Pinworm, Capillariasis and Tapeworms 19.3 Nervous System Infections: Meningitis & CSF Patterns, Encephalitis, Rabies and DOH PEP, Spinal Cord Infections, Tetanus & Botulism, Paralytic Shellfish Poisoning

20 Chapter 20: Microbiology III: Genitourinary, Reproductive, Blood & Skin Infections

20.1 Genitourinary Infections: Cystitis & Pyelonephritis, Urine Diagnostics, Urethritis, Balanoposthitis, Pelvic Inflammatory Disease and Genital Ulcers 20.2 Reproductive Tract Infections & STIs: Syphilis, Genital & Neonatal Herpes, HPV, Molluscum, CMV, Trichomoniasis & Vaginitis, Cervicitis, Prostatitis and Orchitis 20.3 Hematopoietic & Lymphatic Infections: Dengue and Other Hemorrhagic Fevers, Malaria, Lymphatic Filariasis, Lymphogranuloma Venereum and Epstein-Barr Virus 20.4 Integumentary Infections: Viral Exanthems (Measles, Mumps, Rubella, Varicella, Smallpox & Mpox, Fifth Disease), Herpesviruses, Fungal Skin Infections and Tick-Borne Diseases

21 Chapter 21: Microbiology IV: Musculoskeletal & Multisystemic Infections

21.1 Musculoskeletal & Soft-Tissue Infections: Osteomyelitis, Septic & Reactive Arthritis, Pyomyositis & Gas Gangrene, Cellulitis, Necrotizing Fasciitis and Bite Wounds 21.2 Multisystemic Infections I: Septicemia, Septicopyemia & Septic Shock, Leptospirosis and Schistosomiasis japonica 21.3 Multisystemic Infections II: HIV/AIDS Virology, the Philippine Epidemic & RA 11166, Diagnosis (rHIVda), ART, Prevention and Opportunistic Infections including Toxoplasmosis

22 Chapter 22: Obstetrics I: Prenatal Care, Labor & Obstetric Bleeding

22.1 Prenatal Care: Diagnosis of Pregnancy, Maternal Physiology, Dating, Nutrition & Supplements, Screening Tests and the DOH Antenatal Package 22.2 Labor & Parturition: Signs of Labor, Pelvis and Passenger, Stages and Cardinal Movements, Partograph, Fetal Monitoring, Dystocia, Shoulder Dystocia, Operative Delivery, Preterm Labor, PROM and Adolescent Pregnancy 22.3 Early Pregnancy Risks & Bleeding: Hyperemesis, Spontaneous Abortion, Recurrent Loss & Cervical Insufficiency, Ectopic Pregnancy, Hydatidiform Mole & Gestational Trophoblastic Neoplasia 22.4 Hemorrhagic Complications of Pregnancy: Placenta Previa, Abruption, Vasa Previa, Placenta Accreta Spectrum, Uterine Rupture, Third-Stage Management and Postpartum Hemorrhage

23 Chapter 23: Obstetrics II: Fetal, Hypertensive, Medical, Infectious & Postpartum Problems

23.1 Fetal Complications: Malpresentation & Breech, Macrosomia, Fetal Growth Restriction, Amniotic Fluid Disorders, Antepartum Surveillance, Rh Alloimmunization, Multiple Gestation and Post-Term Pregnancy 23.2 Hypertension & Diabetes in Pregnancy: Classification, Preeclampsia Pathogenesis and Prevention, Severe Features, Eclampsia & HELLP, Magnesium Sulfate, Gestational and Pregestational Diabetes 23.3 Medical & Surgical Disorders in Pregnancy: Drug Pharmacokinetics, Epilepsy, Thyroid, Heart Disease, SLE & APS, Asthma, Liver Disorders, Anemia, Dermatoses, Appendicitis, Gallstones, Stones and Trauma 23.4 Perinatal Infections: Triple Elimination (HIV, Syphilis, Hepatitis B), Group B Streptococcus, Chorioamnionitis, Gonorrhea & Chlamydia, Condyloma, Herpes and the TORCH Infections 23.5 Postpartum Care & Complications: Normal Puerperium, Postnatal Visits, Breastfeeding, Puerperal Fever and Infection, Mastitis, Late Hemorrhage, Mood Disorders, VTE and Postpartum Contraception

24 Chapter 24: Gynecology I: Benign Disorders, Infections & Contraception

24.1 Benign Lower Genital Tract Disorders & Pelvic Floor: Vulvar Dermatoses, Bartholin Cysts, Vaginal and Cervical Lesions, Premalignant Lesions, Pelvic Organ Prolapse, Urinary Incontinence and Fistula 24.2 Benign Upper Genital Tract Disorders: Leiomyoma, Adenomyosis & Endometriosis, Endometrial Polyps and Hyperplasia, Functional Cysts and Benign Ovarian Tumors, Adnexal Torsion and Tubal Disease 24.3 Infections of the Female Reproductive Tract: Burden & Screening, Syndromic Management, Vaginitis and Cervicitis, Pelvic Inflammatory Disease & Tubo-Ovarian Abscess, Genital Tuberculosis and Toxic Shock 24.4 Contraception & Family Planning: The RH Law, Effectiveness, Natural and Barrier Methods, Hormonal Methods, IUDs, Permanent Methods, Emergency Contraception and the WHO Eligibility Criteria

25 Chapter 25: Gynecology II: Reproductive Endocrinology, Oncology & Special Issues

25.1 Reproductive Endocrinology & Menstrual Disorders: The Menstrual Cycle, Puberty, Abnormal Uterine Bleeding (PALM-COEIN), Amenorrhea, PCOS, Hyperprolactinemia, Dysmenorrhea, Infertility, Menopause, HRT and Osteoporosis 25.2 Gynecologic Oncology: Cervical Cancer Screening, Staging & Treatment, Endometrial Cancer and Lynch Syndrome, Ovarian Tumors and BRCA, Vulvar and Vaginal Cancer, Survival and Quality of Life 25.3 Contemporary Issues & Pediatric and Adolescent Gynecology: Violence Against Women, Sexual Assault Care, Breast Disorders, Ethics of Maternal-Fetal Conflict, and Gynecologic Problems of Children and Adolescents

26 Chapter 26: Pediatrics I: Newborn, Growth, Nutrition, Immunization & Infections

26.1 The Newborn: Normal Findings and Variants, EINC (Unang Yakap), APGAR, Neonatal Resuscitation, Routine Care & Newborn Screening, Jaundice, Respiratory Distress, Hypoglycemia and Neonatal Sepsis 26.2 Growth, Development & Nutrition: Growth Parameters, Milestones and Red Flags, Speech Delay, Autism, ADHD & Global Delay, Breastfeeding and Feeding, Micronutrient Deficiencies, Malnutrition and Obesity 26.3 Immunization: RA 10152 and the National Immunization Program Schedule, Fully Immunized Child, School-Based Immunization, Other Recommended Vaccines, Vaccine Types, Cold Chain, Contraindications and AEFI 26.4 Pediatric Infectious Diseases: Bacterial (Diphtheria to Congenital Syphilis), Childhood TB, Viral Exanthems and Infections, Dengue in Children, Pediatric HIV, Protozoal, Helminthic and Fungal Infections

27 Chapter 27: Pediatrics II: Respiratory, Cardiovascular, Neurologic & Gastrointestinal Disorders

27.1 Pediatric Respiratory Disorders: IMCI Danger Signs and Cough Assessment, URI, Tonsillitis & Peritonsillar Abscess, Croup, Epiglottitis, Foreign Body, Bronchiolitis, Pneumonia, Pleural Effusion and Complications 27.2 Pediatric Cardiovascular & Collagen Disorders: Heart Sounds and Murmurs, Acyanotic and Cyanotic Congenital Heart Disease, Eisenmenger, Hypercyanotic Spells, Heart Failure, Rheumatic Fever, Hypertension, Endocarditis, Kawasaki, SLE, JIA, Dermatomyositis and Pediatric Resuscitation 27.3 Pediatric CNS Disorders: Febrile Seizures, Epilepsy Syndromes, Status Epilepticus, Meningitis and Encephalitis in Children, Cerebral Palsy, Hydrocephalus & Neural Tube Defects, Headache and Migraine, and Brain Tumors 27.4 Pediatric GI Disorders & Poisoning: Vomiting (Pyloric Stenosis, Atresias, Malrotation, Intussusception, GERD), Diarrhea and IMCI Rehydration Plans, Abdominal Pain, Constipation & Hirschsprung, Jaundice, Biliary Atresia & Choledochal Cyst, Hepatitis, Food Allergy, and Kerosene, Aspirin and INH Poisoning

28 Chapter 28: Pediatrics III: Genitourinary, Endocrine, Hematologic & Oncologic Disorders

28.1 Pediatric Genitourinary Disorders & Child Abuse: UTI and Vesicoureteral Reflux, Post-Streptococcal GN and Other Nephritides, Nephrotic Syndrome, AKI and HUS, CKD, Congenital Urogenital Anomalies, and Recognizing and Reporting Child Abuse 28.2 Pediatric Endocrine & Metabolic Disorders: Short Stature and Growth Hormone, Gigantism, Diabetes Insipidus, Congenital Hypothyroidism, Graves Disease & Goiter, Type 1 Diabetes and DKA, Congenital Adrenal Hyperplasia, Cushing Syndrome, Pheochromocytoma and Adrenal Crisis 28.3 Pediatric Hematology, Allergy & Immunology: Normal Hemogram and Immunoglobulins by Age, Anemias (Iron Deficiency, Thalassemia, G6PD, Spherocytosis, Aplastic), Bleeding Disorders (ITP, Hemophilia, vWD, DIC, Vitamin K), IgA Vasculitis, Rashes and Drug Reactions, Asthma, Allergic Rhinitis and Primary Immunodeficiencies 28.4 Pediatric Oncology & Genetics: Leukemias and Lymphomas, Retinoblastoma, Wilms Tumor, Neuroblastoma, Ewing Sarcoma and Osteosarcoma; Sex Chromosome and Autosomal Disorders, Inborn Errors of Metabolism and the Dysmorphic ("Odd-Looking") Child

29 Chapter 29: Preventive Medicine I: The Physician as Health Care Provider

29.1 The Physician as Health Care Provider I: Natural History of Disease, Disease Causation, Levels of Prevention and Primary Care Across the Clinical Rotations 29.2 The Physician as Health Care Provider II: The Filipino Family and Family Assessment Tools, Health Education and Promotion, Behavior Change Models and Geriatric Medicine 29.3 The Physician as Health Care Provider III: The Primary Health Care Concept (Alma-Ata, Astana, Philippine PHC) and Mental Health in Primary Care under RA 11036

30 Chapter 30: Preventive Medicine II: Philippine Health Care System & Community Medicine

30.1 The Philippine Health Care System: DOH Structure, Levels of Care and Referral, Devolution under RA 7160, the Universal Health Care Act (RA 11223), PhilHealth and YAKAP, and Leading Causes of Morbidity and Mortality 30.2 Epidemiology, Surveillance & Outbreaks: Measures of Disease Occurrence and Association, Rates, Endemic and Epidemic Levels, PIDSR and RA 11332 Notifiable Diseases, the Ten Steps of Outbreak Investigation and Epidemic Curves 30.3 DOH Programs & Environmental Sanitation: TB, Dengue, Rabies, Leprosy, Helminth and Other Disease Programs; the Sanitation Code (PD 856), Water Supply and Potability, Excreta and Solid Waste, Food Sanitation and Health Care Waste 30.4 Community Medicine: Principles of Public Health Administration and Program Planning, Vital Health Indices (Infant and Maternal Mortality), the Ecologic Concept of Health, Lifestyle and Non-Communicable Diseases, Health-Seeking Behavior and Traditional Medicine

31 Chapter 31: Preventive Medicine III: Manager, Researcher & Social Mobilizer

31.1 The Physician as Administrative Manager: Communication and Interpersonal Skills, Teamwork, Adult Learning, Occupational Health (RA 11058), Bioethics, Palliative Care, School Health, Organ Transplantation and Birth and Death Certificates 31.2 The Physician as Researcher I: The Research Process and Proposal, Research Ethics, Study Designs and Meta-Analysis, Demography and Vital Statistics, Evidence-Based Medicine and Quality Assurance 31.3 The Physician as Researcher II: Biostatistics (Data Types, Distributions, Central Tendency and Dispersion, Confidence Intervals, Hypothesis Testing and Test Selection) and Screening Tests (Validity, Predictive Values, Likelihood Ratios, Biases and Program Criteria) 31.4 The Physician as Social Mobilizer and Leader: Philippine Health Laws, Decrees and Executive Orders, Principles of Social Mobilization and Community Organizing, and Disaster Risk Reduction and Management in Health

32 Chapter 32: Pharmacology I: Principles, Cardiovascular & Nervous System Therapeutics

32.1 Pharmacology Foundations: The Pharmacology TOS, Pharmacokinetics, Drug Metabolism and Interactions, Pharmacodynamics, Adverse Drug Reactions and Monitoring, Autonomic Pharmacology, and Philippine Prescribing Rules 32.2 Cardiovascular Pharmacology I: Cardiac Arrest and ACLS Drugs, Bradycardia and Complete Heart Block, Antiarrhythmics, Anticoagulation in Atrial Fibrillation, Antianginals, ACS Therapy and Fibrinolysis, Pericarditis and Endocarditis Regimens 32.3 Cardiovascular Pharmacology II: Antihypertensives and Diuretics, Hypertensive Emergencies, Vasopressors and Inotropes in Shock, Heart Failure GDMT and Digoxin, and Lipid-Lowering Therapy 32.4 Nervous System Pharmacology I: Antiseizure Drugs and Status Epilepticus, Headache and Migraine, Vertigo, Stroke Thrombolysis and Secondary Prevention, Encephalopathy, Dementia, ADHD, Parkinson Disease and Movement Disorders, Raised Intracranial Pressure and CNS Infections

33 Chapter 33: Pharmacology II: Psychiatric, Respiratory & Genitourinary Therapeutics

33.1 Nervous System Pharmacology II: Antidepressants and Their Toxicity, Serotonin Syndrome, Anxiolytics and Hypnotics, Antipsychotics, EPS and NMS, Lithium and Mood Stabilizers, Sleep Disorders, Agitation and Alcohol Withdrawal 33.2 Respiratory Pharmacology: Cough and Colds, Allergic Rhinitis, Asthma (Controllers, Relievers, Exacerbations), COPD, Anti-TB Drugs, Antibiotics for Pneumonia and Bronchitis, and Lung Cancer Therapy 33.3 Genitourinary Pharmacology I: Antimicrobial Classes and Toxicities, and Drug Treatment of UTI, Pyelonephritis, Gonorrhea, Chlamydia, Syphilis, Genital Herpes, Genital Warts, PID, Vaginitis, Prostatitis and Orchitis 33.4 Genitourinary Pharmacology II: Kidney Stones, Nephrotic and Nephritic Disease, Drug Dosing in Kidney Disease and Hyperkalemia, Benign Prostatic Hyperplasia, Erectile Dysfunction, Renal Cell Carcinoma and Prostate Cancer Therapy

34 Chapter 34: Pharmacology III: Digestive, Endocrine, Skin & Musculoskeletal Therapeutics

34.1 Digestive Pharmacology: Portal Hypertension and Variceal Bleeding, Acid-Peptic Disease, H. pylori and GERD, Antiemetics, Laxatives and Antidiarrheals, Biliary and Pancreatic Disease, GI Infections and Parasites, Viral Hepatitis, C. difficile, Candidiasis and GI Cancer Chemotherapy 34.2 Endocrine Pharmacology I: Diabetes Mellitus Drugs (Metformin, Sulfonylureas, SGLT2 Inhibitors, GLP-1 Agonists, DPP-4 Inhibitors, Thiazolidinediones, Insulins), Choosing Therapy by Comorbidity, DKA and HHS, and Hypoglycemia 34.3 Endocrine Pharmacology II: Pituitary Disorders (GH Deficiency, Acromegaly, Prolactinoma, Diabetes Insipidus, Panhypopituitarism), Thyroid Drugs and Thyroid Storm, Calcium and Parathyroid Disorders, Adrenal Disorders and Corticosteroids 34.4 Cutaneous and Musculoskeletal Pharmacology: Cellulitis and Abscess, Drug-Induced Skin Reactions (SJS/TEN), Pain Management (Paracetamol, NSAIDs, Opioids), Osteoporosis, Rheumatoid Arthritis and Osteoarthritis, Septic and TB Arthritis, Gout, SLE and Psoriasis

35 Chapter 35: Surgery I: Basic Surgical Principles

35.1 Basic Surgical Principles I: The Surgery TOS, Fluids and Electrolytes, Acid-Base Balance, the Metabolic Response to Injury, Surgical Nutrition and Blood Transfusion 35.2 Basic Surgical Principles II: Shock and Surgical Critical Care, Hemorrhagic Shock and Massive Transfusion, ATLS Primary and Secondary Survey, Chest and Abdominal Trauma, Head and Spine Injury, Pelvic Fractures and Burns 35.3 Basic Surgical Principles III: Preoperative Assessment, Wound Healing, Surgical Infection and Asepsis, Postoperative Fever, Surgical Oncology, Immunology and Transplantation, Anesthesia and Patient Safety

36 Chapter 36: Surgery II: Abdomen, Breast & Hernia

36.1 Abdomen I: Esophagus (Hiatal Hernia, GERD, Achalasia, Caustic Injury, Barrett, Boerhaave, Mallory-Weiss, Cancer), Stomach and Duodenum (Peptic Ulcer Complications, Upper GI Bleeding, Gastric Cancer, GIST), Small Bowel (Obstruction, Ileus, Tumors, Typhoid and TB), Retroperitoneum and Abdominal Wall 36.2 Abdomen II: Gallstones, Cholecystitis, Choledocholithiasis and Cholangitis, Obstructive Jaundice, Liver (Cirrhosis, Portal Hypertension, Abscesses, Tumors and Hepatocellular Carcinoma), Pancreas (Acute and Chronic Pancreatitis, Pancreatic Cancer) and Spleen (Splenectomy, OPSI) 36.3 Abdomen III: Acute Appendicitis, Colonic Obstruction and Volvulus, Lower GI Bleeding, Diverticular Disease, Colorectal Polyps and Cancer, Hemorrhoids, Anal Fissure, Perianal Abscess and Fistula 36.4 Breast, Hernia and Skin and Soft Tissue: Benign Breast Masses, Breast Cancer Evaluation and Treatment, Groin and Abdominal Wall Hernias, Benign Skin and Soft-Tissue Tumors, Skin Cancers and Soft-Tissue Sarcoma

37 Chapter 37: Surgery III: Surgical Specialties

37.1 Head and Neck, Thyroid, Parathyroid, Endocrine and Bariatric Surgery and Otorhinolaryngology: Neck Masses and Head and Neck Cancer, Salivary Glands, Thyroid Nodules and Cancer, Goiter and Hyperthyroidism Surgery, Hyperparathyroidism, Adrenal Surgery, Bariatric Surgery, Nasal Polyps, Epistaxis, Vertigo, Hearing Loss and ENT Infections 37.2 Specialty I: Neurosurgery (Raised Intracranial Pressure and Herniation, Head Injury and Hematomas, Spontaneous Intracranial Hemorrhage, CNS and Peripheral Nerve Tumors, Spinal Cord Compression, Neurosurgical Infections) and Ophthalmology (Glaucoma, Cataract, Ophthalmic Emergencies) 37.3 Specialty II: Thoracic and Cardiovascular Surgery (Pleural Effusion and Empyema, Lung Cancer, Mediastinal Masses, Surgical Heart Disease, Aortic Aneurysm and Dissection, Peripheral Arterial and Venous Disease), Urology (Stones, Infections, Torsion, BPH, Urologic Tumors) and Gynecologic Surgery 37.4 Specialty III: Plastic and Reconstructive Surgery (Skin Grafts and Flaps, Cleft Lip and Palate, Facial Fractures, Hand Injuries), Orthopedics (Fractures, Dislocations, Bone and Joint Infections, Bone Tumors) and Pediatric Surgery (Hernias, CDH, Esophageal Atresia, Obstruction, Hirschsprung Disease, Neonatal Jaundice, Tumors)

38 Chapter 38: Medicine I: Cardiovascular, Digestive & Endocrine Medicine

38.1 Cardiovascular Medicine I: Hypertension and Secondary Causes, Dyslipidemia, Stable Angina and Acute Coronary Syndromes, Post-MI Complications, Heart Failure and Shock Syndromes 38.2 Cardiovascular Medicine II: Tachyarrhythmias and Bradyarrhythmias, Atrial Fibrillation, Sudden Cardiac Death and Brugada Syndrome, Cardiac Arrest, Valvular and Rheumatic Heart Disease, Infective Endocarditis, Myocarditis and Pericardial Disease 38.3 Gastroenterology and Hepatology: GERD and Peptic Ulcer Disease, Upper and Lower GI Bleeding, Diarrhea and GI Infections, Acute Pancreatitis and Biliary Disease, Viral Hepatitis, Cirrhosis and Portal Hypertension, Liver and GI Cancers 38.4 Endocrinology: Diabetes Mellitus Diagnosis, Treatment and Complications, DKA and HHS, Thyroid Disease, Pituitary Disorders, Adrenal Disorders (Cushing, Aldosteronism, Addison, Pheochromocytoma), Calcium and Parathyroid Disorders, Obesity and Metabolic Syndrome

39 Chapter 39: Medicine II: Hematology, Systemic Infections, Renal & Respiratory Medicine

39.1 Hematology, Immunology and Systemic Infections: Anemias (Iron Deficiency, Thalassemia, G6PD Deficiency, Megaloblastic, Hemolytic), Acute and Chronic Leukemias and Their Emergencies, Allergic Disorders, Dengue in Adults, COVID-19, Malaria and HIV/AIDS Opportunistic Infections 39.2 Nephrology: Acute Kidney Injury, Chronic Kidney Disease and Dialysis, Sodium and Potassium Disorders, Acid-Base Analysis, Urinary Tract Infections, Glomerular Diseases (Nephritic and Nephrotic), Kidney Stones, Renal Tumors and Sexually Transmitted Infections 39.3 Pulmonology and Critical Care: Acute Respiratory Failure and Oxygen Therapy, Bronchial Asthma, COPD, Community- and Hospital-Acquired Pneumonia, Pulmonary Tuberculosis and TB Infection, Pulmonary Embolism, Lung Cancer and ARDS

40 Chapter 40: Medicine III: Rheumatology, Dermatology, Neurology, Rehabilitation & Psychiatry

40.1 Rheumatology and Dermatology: Approach to Arthritis, Osteoarthritis, Rheumatoid Arthritis, Gout, Spondyloarthritis, SLE and Other Connective Tissue Diseases, Vasculitis and Myalgias, Bone Tumors, Common Skin Lesions, Skin Infections and Infestations, Eczema, Psoriasis, Severe Drug Eruptions and Skin Signs of Systemic Disease 40.2 Neurology and Rehabilitation Medicine: Stroke and TIA (Localization, Thrombolysis, Thrombectomy, Secondary Prevention), Intracranial Hemorrhage, Seizures and Status Epilepticus, Meningitis and Encephalitis, Tetanus and Rabies, Parkinsonism, Neuromuscular and Degenerative Diseases, Dementia, CNS Tumors, Post-Stroke Rehabilitation and Musculoskeletal Disorders 40.3 Psychiatry: Mental Status Examination, Depressive Disorders, Bipolar Disorder, Schizophrenia and Other Psychoses, Anxiety Disorders, OCD and Trauma-Related Disorders, Substance Use, and Acute Psychiatric Emergencies (Suicide Risk, Agitation, Withdrawal, Wernicke Encephalopathy)

33.3 Genitourinary Pharmacology I: Antimicrobial Classes and Toxicities, and Drug Treatment of UTI, Pyelonephritis, Gonorrhea, Chlamydia, Syphilis, Genital Herpes, Genital Warts, PID, Vaginitis, Prostatitis and Orchitis

Key Takeaways Explain This Topic AI

Nitrofurantoin for 5 days or single-dose fosfomycin treats uncomplicated cystitis; pyelonephritis needs a fluoroquinolone or ceftriaxone guided by culture.

Gonorrhea is treated with ceftriaxone 500 mg IM once; chlamydia with doxycycline 100 mg twice daily for 7 days (azithromycin in pregnancy).

Benzathine penicillin G 2.4 million units IM once treats early syphilis; neurosyphilis needs IV aqueous penicillin for 10 to 14 days.

Metronidazole treats trichomoniasis and bacterial vaginosis; vulvovaginal candidiasis is treated with an azole, and partners are treated only for trichomoniasis.

Aminoglycosides are nephrotoxic and ototoxic, fluoroquinolones cause tendinopathy and QT prolongation, and TMP-SMX causes hyperkalemia, rash and hemolysis in G6PD deficiency.

Last updated: October 2026

Why this area matters

The TOS genitourinary area asks you to choose drugs for urinary infections, STIs, genital ulcers and warts, and PID, and to know their adverse effects and interactions. Antimicrobial resistance (ESBL E. coli , fluoroquinolone-resistant gonorrhea) is a growing problem in the Philippines, so first-line choices follow current guidelines and local antibiograms.

Antibacterial Cell Wall Inhibitors: Beta-Lactams & Glycopeptides

Bacterial cell walls consist of peptidoglycan polymers cross-linked by transpeptidase enzymes, collectively known as Penicillin-Binding Proteins (PBPs) . Beta-lactam antibiotics contain a four-membered beta-lactam ring that acts as a structural analog of the D-Ala-D-Ala substrate, irreversibly inhibiting PBPs and triggering bacterial autolysin-mediated cell wall lysis.

Penicillins

Natural Penicillins (Penicillin G IV, Penicillin V oral) : Active against Treponema pallidum (syphilis drug of choice), Streptococcus pyogenes (Group A Strep), Actinomyces , and Clostridium perfringens . Rapidly degraded by staphylococcal penicillinase.

Aminopenicillins (Ampicillin, Amoxicillin) : Extended Gram-negative spectrum covering "HELPSS" ( H. influenzae, E. coli, Listeria monocytogenes, Proteus mirabilis, Salmonella, Shigella ) and Enterococcus faecalis . Sensitive to beta-lactamases; combined with beta-lactamase inhibitors ( Amoxicillin-Clavulanic acid, Ampicillin-Sulbactam ) to restore activity against beta-lactamase-producing MSSA, H. influenzae , and Bacteroides fragilis . Ampicillin causes a non-allergic maculopapular rash when administered in patients with Epstein-Barr Virus (EBV) infectious mononucleosis.

Antistaphylococcal Penicillins (Oxacillin, Nafcillin, Cloxacillin, Dicloxacillin) : Contain bulky lipophilic R-groups that sterically shield the beta-lactam ring from staphylococcal penicillinase. Narrow spectrum; active against Methicillin-Susceptible Staphylococcus aureus (MSSA) and streptococci. Completely inactive against MRSA (MRSA alters PBP2a, conferring resistance to all standard beta-lactams). Nafcillin causes interstitial nephritis and neutropenia; eliminated via biliary excretion (no dosage adjustment in renal failure).

Antipseudomonal Penicillins (Piperacillin-Tazobactam) : Broad spectrum covering Pseudomonas aeruginosa , enteric Gram-negative bacilli, and anaerobes.

Cephalosporins (Generations 1 through 5)

1st Generation (Cefazolin IV, Cephalexin oral) : Active against Gram-positive cocci (MSSA, streptococci) and "PEcK" ( Proteus, E. coli, Klebsiella ). Cefazolin is the surgical antimicrobial prophylaxis drug of choice.

2nd Generation (Cefuroxime oral/IV, Cefoxitin IV, Cefotetan IV) : Expanded Gram-negative activity ("HenPEcK": H. influenzae, Enterobacter, Neisseria, Proteus, E. coli, Klebsiella ). Cefoxitin and cefotetan cover anaerobes ( Bacteroides fragilis ) and are used in pelvic inflammatory disease and intra-abdominal surgery. Cefotetan contains an N-methylthiotetrazole (NMTT) side chain that inhibits aldehyde dehydrogenase, causing disulfiram-like reactions with alcohol, and inhibits vitamin K epoxide reductase, causing hypoprothrombinemia and bleeding.

3rd Generation (Ceftriaxone, Cefotaxime, Ceftazidime) : Enhanced Gram-negative coverage, resistant to many beta-lactamases, penetrate the blood-brain barrier. Ceftriaxone is first-line for community-acquired bacterial meningitis ( S. pneumoniae, N. meningitidis ), Neisseria gonorrhoeae , and severe CAP; eliminated predominantly via biliary excretion (no dosage adjustment in renal failure); avoided in hyperbilirubinemic neonates (it displaces bilirubin from albumin) and never given to neonates with IV calcium-containing solutions (fatal precipitates); it can also cause biliary sludging ("pseudolithiasis"). Ceftazidime has potent activity against Pseudomonas aeruginosa but poor Gram-positive coverage.

4th Generation (Cefepime) : Broad spectrum combining Gram-positive coverage of 1st gen and antipseudomonal/Gram-negative coverage of 3rd gen. Stable against plasmid- and chromosomally mediated AmpC beta-lactamases. Causes neurotoxicity (encephalopathy, myoclonus, seizures) in renal impairment if dose is unadjusted.

5th Generation (Ceftaroline) : Binds with high affinity to modified PBP2a , conferring bactericidal activity against Methicillin-Resistant Staphylococcus aureus (MRSA) and multidrug-resistant S. pneumoniae . Lacks activity against Pseudomonas aeruginosa .

Carbapenems & Monobactams

Carbapenems (Meropenem, Imipenem-Cilastatin, Ertapenem) : Ultra-broad-spectrum bactericidal agents; stable against extended-spectrum beta-lactamases (ESBLs). Imipenem is always formulated with cilastatin , an inhibitor of renal dehydropeptidase I on brush border membranes; cilastatin prevents renal inactivation of imipenem and prevents formation of a nephrotoxic metabolite. Imipenem lowers the seizure threshold; Meropenem has lower seizure potential and is preferred for CNS infections. Ertapenem lacks coverage against "PEA" ( Pseudomonas aeruginosa, Enterococcus, Acinetobacter ).

Monobactams (Aztreonam) : Binds PBP3; active strictly against aerobic Gram-negative bacilli (including Pseudomonas ); completely lacks Gram-positive and anaerobic activity. Possesses zero cross-reactivity with other beta-lactams (safe in patients with severe IgE-mediated penicillin allergies, except those with specific ceftazidime allergy due to identical side chain).

Glycopeptides: Vancomycin

Mechanism : Inhibits cell wall synthesis by binding directly with high affinity to the D-Ala-D-Ala terminus of peptidoglycan precursors, sterically blocking transglycosylase polymerization and transpeptidase cross-linking. Active strictly against Gram-positive bacteria (MRSA, coagulase-negative staphylococci, Enterococcus faecalis ). Oral vancomycin is not absorbed systemically and is reserved exclusively for Clostridioides difficile colitis.

Adverse Effects :

Red Man Syndrome : Rate-dependent, non-IgE direct activation of mast cells and histamine release, resulting in diffuse pruritus, erythema, and flushing of the face, neck, and upper torso. Prevented by slowing infusion rate ( > 60 – 120 minutes > 60\text{--}120\text{ minutes} > 60 – 120 minutes ) and pretreating with antihistamines.

Nephrotoxicity : Dose-dependent acute tubular injury and interstitial nephritis; risk multiplied when combined with aminoglycosides or piperacillin-tazobactam.

Ototoxicity : High trough levels cause cochlear hair cell injury; often permanent.

Vancomycin Resistance (VRE and VRSA) : Plasmid-mediated replacement of the terminal D-Ala-D-Ala dipeptide with D-Ala-D-Lactate (or D-Ala-D-Serine), reducing vancomycin binding affinity by 1,000-fold.

Ribosomal Protein Synthesis Inhibitors (30S & 50S)

Bacterial 70S ribosomes consist of a 30S and a 50S subunit. Inhibitors exploit structural differences from eukaryotic 80S ribosomes.

30S Subunit Inhibitors ("Buy AT 30")

Aminoglycosides (Gentamicin, Amikacin, Tobramycin) :

Mechanism : Irreversibly bind the 30S subunit, freezing the 30S initiation complex and inducing mRNA codon misreading; bactericidal. Entry into bacterial cytoplasm requires an oxygen-dependent active transport system ; completely inactive against obligate anaerobes ( Clostridium, Bacteroides ). Synergistic with beta-lactams, which disrupt the cell wall to facilitate aminoglycoside entry. Exhibit concentration-dependent killing and prolonged post-antibiotic effect (PAE) , enabling once-daily (extended-interval) dosing.

Toxicities :

Nephrotoxicity ( 10 – 25 % 10\text{--}25\% 10 – 25% ): Non-oliguric acute tubular necrosis (ATN); accumulates in renal proximal tubular cells; usually reversible.

Ototoxicity : Destroys hair cells in the organ of Corti (cochleotoxicity: hearing loss; Amikacin) and vestibular apparatus (vestibulotoxicity: vertigo, ataxia; Gentamicin); permanent and irreversible.

Neuromuscular Blockade : Inhibits presynaptic calcium influx and acetylcholine release; contraindicated in Myasthenia Gravis.

Tetracyclines (Doxycycline, Minocycline, Tetracycline) :

Mechanism : Reversibly bind the 30S ribosomal subunit, blocking aminoacyl-tRNA attachment to the ribosomal acceptor (A) site; bacteriostatic. Broad spectrum covering atypicals ( Mycoplasma, Chlamydia ), zoonoses ( Rickettsia, Borrelia, Leptospira ). Doxycycline is the first-line agent for leptospirosis chemoprophylaxis and treatment in the Philippines.

Toxicities : Chelated by multivalent cations ( C a 2 + , M g 2 + , F e 2 + , A l 3 + Ca^{2+}, Mg^{2+}, Fe^{2+}, Al^{3+} C a 2 + , M g 2 + , F e 2 + , A l 3 + ; dairy, antacids, iron supplements impair absorption); binds calcium in newly formed bone and teeth, causing permanent teeth discoloration (yellow-brown) and enamel hypoplasia; generally avoided in pregnancy and in children under 8, although short courses of doxycycline are used at any age for serious infections such as rickettsial disease. Also causes photosensitivity and chemical pill esophagitis (must take with a full glass of water sitting upright). Doxycycline is eliminated non-renally via feces and requires no renal dosage adjustment.

50S Subunit Inhibitors ("CELL at 50")

Macrolides (Azithromycin, Clarithromycin, Erythromycin) :

Mechanism : Bind 23S rRNA of the 50S subunit, blocking peptidyltransferase and transpeptidase translocation. Active against atypical respiratory pathogens ( Mycoplasma, Chlamydia, Legionella ), Bordetella pertussis , and CAP.

Toxicities :

QT Interval Prolongation : Risk of Torsades de pointes.

CYP3A4 Inhibition : Erythromycin and clarithromycin are potent CYP3A4 inhibitors (raise levels of statins, theophylline, warfarin); Azithromycin does not inhibit CYP3A4 .

Gastrointestinal Motility Stimulation: Erythromycin directly binds smooth muscle motilin receptors, producing abdominal cramping and diarrhea.

Chloramphenicol :

Mechanism : Reversibly binds 50S subunit, inhibiting peptidyl transferase; bacteriostatic. Broad spectrum with excellent CNS penetration.

Toxicities :

Dose-dependent bone marrow suppression (reversible anemia/leukopenia).

Idiosyncratic, dose-independent Aplastic Anemia (irreversible and usually fatal pancytopenia; occurs weeks to months after therapy).

Gray Baby Syndrome : In neonates and premature infants lacking mature hepatic UDP-glucuronyltransferase enzyme activity with low renal excretion. Toxic accumulation disrupts mitochondrial ribosomes, manifesting as vomiting, flaccidity, hypothermia, ashen gray skin discoloration, metabolic acidosis, and cardiovascular collapse.

Clindamycin :

Mechanism : Lincosamide; binds 50S subunit, inhibiting peptide bond formation. Active against Gram-positive cocci (including community-acquired MRSA) and anaerobes above the diaphragm (oral cavity anaerobes, Fusobacterium ; aspiration pneumonia, lung abscesses, dental infections). Major adverse effect: Pseudomembranous colitis caused by Clostridioides difficile overgrowth.

  • Nucleic Acid Inhibitors, Antifungals & Antivirals
  • Fluoroquinolones & Antifolates

Fluoroquinolones (Ciprofloxacin, Levofloxacin, Moxifloxacin) :

Mechanism : Inhibit bacterial DNA gyrase (topoisomerase II) in Gram-negative bacteria and topoisomerase IV in Gram-positive bacteria, inducing double-stranded DNA breaks; bactericidal. Ciprofloxacin has high potency against Pseudomonas aeruginosa and Gram-negative enteric bacilli. Levofloxacin and Moxifloxacin are "respiratory quinolones" with expanded coverage against Streptococcus pneumoniae and atypicals.

Toxicities :

Tendinitis and Tendon Rupture (most commonly Achilles tendon; boxed warning; risk increased in patients > 60 > 60 > 60 years, athletes, and concurrent systemic corticosteroids).

QT Interval Prolongation and dysglycemia.

Neurotoxicity, peripheral neuropathy, and collagen degradation (aortic aneurysm/dissection warning).

Generally avoided in pregnancy, breastfeeding and children (cartilage damage in juvenile animals), unless no safer alternative exists.

Trimethoprim-Sulfamethoxazole (TMP-SMX / Cotrimoxazole) :

Mechanism : Sequential folate synthesis inhibition. Sulfamethoxazole competitively inhibits dihydropteroate synthase (structural analog of PABA); Trimethoprim inhibits dihydrofolate reductase (DHFR) . Synergistic bactericidal combination. Spectrum: Pneumocystis jirovecii pneumonia (PCP; treatment and prophylaxis in HIV/AIDS), community-acquired MRSA, Nocardia , Stenotrophomonas maltophilia , urinary tract infections.

Toxicities :

Hypersensitivity reactions: Rash, erythema multiforme, Stevens-Johnson Syndrome (SJS) , and Toxic Epidermal Necrolysis (TEN).

Hematologic: Megaloblastic anemia (preventable with folinic acid / leucovorin), leukopenia, and acute hemolytic anemia in patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency .

Hyperkalemia : Trimethoprim structurally resembles amiloride and blocks apical epithelial sodium channels (ENaC) in renal collecting tubule principal cells.

Kernicterus : Sulfonamides displace unconjugated bilirubin from albumin binding sites; strictly contraindicated in the third trimester of pregnancy and in neonates < 2 < 2 < 2 months of age.

Antifungal Therapeutics

Amphotericin B : Polyene macrolide; binds to ergosterol in fungal cell membranes, forming polar transmembrane pores that leak intracellular potassium ( K + K^+ K + ) and magnesium ( M g 2 + Mg^{2+} M g 2 + ), causing fungal cell death. Broadest spectrum for life-threatening systemic fungal infections (cryptococcal meningitis, invasive mucormycosis, histoplasmosis).

Toxicities : Acute infusion reactions ("shake and bake": fever, chills, rigors; managed with premedication); dose-dependent Nephrotoxicity (induces renal afferent arteriolar vasoconstriction and tubular damage, causing renal tubular acidosis Type 1, massive potassium and magnesium wasting, and normocytic normochromic anemia due to decreased erythropoietin production). Hydration with normal saline prior to infusion reduces renal toxicity. Liposomal formulations (AmBisome) significantly reduce nephrotoxicity. Nystatin is a polyene with identical mechanism, used topically for oral candidiasis (swish and swallow) or diaper dermatitis due to systemic toxicity.

Azoles (Fluconazole, Itraconazole, Voriconazole, Posaconazole) : Inhibit fungal cytochrome P450 enzyme 14 α 14\alpha 14 α -sterol demethylase , blocking the conversion of lanosterol to ergosterol, destabilizing the fungal cell membrane.

Fluconazole : Excellent CSF penetration, high urinary excretion; first-line for cryptococcal meningitis maintenance and Candida infections.

Voriconazole : Drug of choice for invasive Aspergillosis . Causes transient visual disturbances (photopsia, altered color perception in 30%) and visual hallucinations.

Class toxicity : All azoles are potent CYP450 inhibitors and can cause hepatotoxicity and QT prolongation.

Echinocandins (Caspofungin, Micafungin, Anidulafungin) : Inhibit β \beta β -(1,3)-D-glucan synthase , disrupting fungal cell wall synthesis (analogous to beta-lactams in bacteria). Active against Candida (including azole-resistant strains) and Aspergillus . Extremely well tolerated with low toxicity.

Antiviral Therapeutics & Philippine HIV Regimens

Acyclovir & Valacyclovir : Guanosine analogs selectively monophosphorylated by viral thymidine kinase (present in HSV-1, HSV-2, and VZV), then converted by host cellular kinases into acyclovir triphosphate, which inhibits viral DNA polymerase and acts as a DNA chain terminator. Uninfected host cells do not phosphorylate the drug, conferring high selectivity. Valacyclovir is an L-valyl ester prodrug with 3- to 5-fold higher oral bioavailability. Toxicities: Crystalline nephropathy (intravenous acyclovir precipitates in renal tubules; preventable by slow infusion and aggressive intravenous hydration) and neurotoxicity/delirium.

Oseltamivir : Oral prodrug converted to oseltamivir carboxylate; selectively inhibits influenza A and B neuraminidase , preventing the enzymatic cleavage of sialic acid residues and trapping newly replicated virions on host cell surfaces, halting viral spread. Must be initiated within 48 hours of symptom onset to significantly shorten illness duration.

Philippine DOH HIV Antiretroviral Therapy (ART) :

The national first-line regimen for adolescents and adults living with HIV is the fixed-dose combination TLD :

Tenofovir Disoproxil Fumarate (TDF) : Nucleotide Reverse Transcriptase Inhibitor (NRTI); competitive inhibitor of viral reverse transcriptase and chain terminator. Toxicities: Proximal renal tubular dysfunction (Fanconi syndrome) and loss of bone mineral density (osteopenia/osteoporosis); monitor serum creatinine and urinalysis.

Lamivudine (3TC) : Nucleoside Reverse Transcriptase Inhibitor (NRTI); well tolerated; dual activity against Hepatitis B virus (HBV).

Dolutegravir (DTG) : Second-generation Integrase Strand Transfer Inhibitor (INSTI); binds the active site of HIV integrase, preventing insertion of proviral viral DNA into the host genome. Rapid viral load suppression, high genetic barrier to resistance; adverse effects: headache, insomnia, weight gain.

Regimens for genitourinary infections

Condition First-line treatment Notes

Uncomplicated cystitis Nitrofurantoin 100 mg twice daily for 5 days, or fosfomycin 3 g once TMP-SMX for 3 days only where resistance is under 20%; avoid fluoroquinolones for simple cystitis

Pyelonephritis Oral ciprofloxacin or levofloxacin if susceptible, or IV ceftriaxone if severe Adjust to culture; ESBL organisms need a carbapenem

UTI or asymptomatic bacteriuria in pregnancy Cephalexin, amoxicillin-clavulanate or nitrofurantoin (avoided near term) Avoid fluoroquinolones and tetracyclines; avoid TMP-SMX in the first trimester and near term

Gonorrhea (urethritis, cervicitis) Ceftriaxone 500 mg IM once Add doxycycline if chlamydia is not excluded; treat partners

Chlamydia Doxycycline 100 mg twice daily for 7 days Azithromycin 1 g in pregnancy

Primary, secondary or early latent syphilis Benzathine penicillin G 2.4 million units IM once Late latent: weekly for 3 weeks; neurosyphilis: aqueous penicillin G IV; desensitize in pregnancy

Genital herpes Acyclovir 400 mg three times daily (or valacyclovir) for 7 to 10 days in a first episode Episodic or suppressive therapy for recurrences

  • Chancroid Azithromycin 1 g once or ceftriaxone 250 mg IM
  • Lymphogranuloma venereum Doxycycline for 21 days

Genital warts Patient-applied podophyllotoxin or imiquimod ; provider-applied cryotherapy or trichloroacetic acid Podophyllin and imiquimod are avoided in pregnancy

PID (outpatient) Ceftriaxone 500 mg IM once plus doxycycline and metronidazole for 14 days Inpatient IV regimens for severe disease or abscess

  • Trichomoniasis Metronidazole 500 mg twice daily for 7 days (women) Treat partners
  • Bacterial vaginosis Metronidazole orally for 7 days or vaginal gel No routine partner treatment
  • Vulvovaginal candidiasis Topical azole or fluconazole 150 mg once Topical azoles in pregnancy

Acute bacterial prostatitis Fluoroquinolone or TMP-SMX for 2 to 4 weeks (longer if chronic) Good prostate penetration

Epididymo-orchitis Under 35: ceftriaxone plus doxycycline; older or enteric: levofloxacin Scrotal support, analgesia

Postpartum endometritis (metritis) IV clindamycin plus gentamicin Until afebrile for 24 to 48 hours

Metronidazole:

forms toxic free radicals in anaerobes and protozoa;

adverse effects are a metallic taste , nausea, neuropathy with long use, and a possible disulfiram-like reaction with alcohol.

Nitrofurantoin:

  • concentrates in urine, so it is not used for pyelonephritis ;
  • avoid it with low creatinine clearance;

it causes pulmonary reactions , neuropathy, and hemolysis in G6PD deficiency or in a newborn exposed near term.

Penicillin allergy:

  • most reported penicillin allergies are not true allergies;
  • cephalosporins with dissimilar side chains can usually be given unless the reaction was severe;

desensitization is needed for syphilis in pregnancy.